Tom Dekker

Mr. Tom Dekker


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2020 in Drug Discovery Today: Technologies
Verified
Journal Article
Closed access
DHDavid Hamilton
David Hamilton
TDTom Dekker
Tom Dekker
HKHanna F. Klein
Hanna F. Klein
GJGuido V. Janssen
Guido V. Janssen
MWMaikel Wijtmans
Maikel Wijtmans
IEIwan de Esch
Iwan de Esch

13 February 2023 in Molecules
Verified
Journal Article
Open access
PDF file
TDTom Dekker
Tom Dekker
JHJaap Harteveld
Jaap Harteveld
GWGábor Wágner
Gábor Wágner
MVMax C. M. de Vries
Max C. M. de Vries
HCHans Custers
Hans Custers
MWMaikel Wijtmans
Maikel Wijtmans
Biomass-derived molecules can provide a basis for sustainable drug discovery. However, their full exploration is hampered by the dominance of millions of old-fashioned screening compounds in classical high-throughput screening (HTS) libraries frequently utilized. We propose a fragment-based drug discovery (FBDD) approach as an efficient method to navigate biomass-derived drug space. Here, we perform a proof-of-concept study with dihydrolevoglucosenone (CyreneTM), a pyrolysis product of cellulose. Diverse synthetic routes afforded a 100-membered fragment library with a diversity in functional groups appended. The library overall performs well in terms of novelty, physicochemical properties, aqueous solubility, stability, and three-dimensionality. Our study suggests that Cyrene-based fragments are a valuable green addition to the drug discovery toolbox. Our findings can help in paving the way for new hit drug candidates that are based on renewable resources.

2 May 2023 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Open access
TDTom Dekker
Tom Dekker
MJMathilde A. C. H. Janssen
Mathilde A. C. H. Janssen
CSChristina Sutherland
Christina Sutherland
RARene W. M. Aben
Rene W. M. Aben
HSHans W. Scheeren
Hans W. Scheeren
IEIwan de Esch
Iwan de Esch
The recent success of fragment-based drug discovery (FBDD) is inextricably linked to adequate library design. To guide the design of our fragment libraries, we have constructed an automated workflow in the open-source KNIME software. The workflow considers chemical diversity and novelty of the fragments, and can also take into account the three-dimensional (3D) character. This design tool can be used to create large and diverse libraries but also to select a small number of representative compounds as a focused set of unique screening compounds to enrich existing fragment libraries. To illustrate the procedures, the design and synthesis of a 10-membered focused library is reported based on the cyclopropane scaffold, which is underrepresented in our existing fragment screening library. Analysis of the focused compound set indicates significant shape diversity and a favorable overall physicochemical profile. By virtue of its modular setup, the workflow can be readily adjusted to design libraries that focus on other than 3D

29 January 2026 in RSC Medicinal Chemistry
Verified
Journal Article
Open access
PDF file
TDTom Dekker
Tom Dekker
OLOscar P. J. van Linden
Oscar P. J. van Linden
HLHerman Lim
Herman Lim
MDMabel E. Dekker
Mabel E. Dekker
HVHenry F. Vischer
Henry F. Vischer
IEIwan de Esch
Iwan de Esch
Fragment-based drug discovery enables translation of novel (3D) chemistries into biologically relevant hit matter, as demonstrated by the identification and optimization of a cyclobutane-based 3D fragment into a potent histamine H 1 receptor ligand.

11 January 2026
Verified
Thesis
Open access
TDTom Dekker
Tom Dekker
In the late 1990s, fragment-based drug discovery (FBDD) emerged as a novel method for hit identification, complementing existing strategies such as high-throughput screening (HTS). Rather than screening drug-sized molecules, FBDD focuses on smaller fragment-sized compounds with molecular weights of up to 300 Da. Owing to their reduced complexity, fragments sample chemical space efficiently, which allows for the use of significantly smaller libraries that typically comprise only a few thousand compounds. Historically, fragment libraries have been dominated by relatively flat, (hetero)aromatic scaffolds. Although such libraries have successfully yielded several clinically approved drugs and numerous clinical candidates, 2D fragments explore only a narrow region of chemical space and may bias discovery toward planar chemotypes with suboptimal three-dimensional fit. In contrast, 3D fragments offer greater diversity in terms of shape and exit vectors, which, depending on the target, may better complement the three-dimensional nature of protein binding sites. This has led to growing interest in incorporating 3D fragments alongside traditional 2D libraries. However, 3D fragments also present challenges, including reduced synthetic accessibility and potentially lower hit rates. This thesis explores the challenges, as well as the opportunities, associated with 3D fragments across the key stages of fragment-based drug discovery. Following an introduction in Chapter 1, the thesis commences in Chapter 2 with a comparative analysis of the metrics commonly used to quantify the three-dimensional character of fragments, including the fraction of sp3-hybridized carbons (Fsp3), Plane of Best Fit (PBF), and Principal Moments of Inertia (PMI). Implications for their use in (fragment) library design are discussed. Chapter 3 describes the development of an automated, open-source workflow for fragment library design. The workflow is highly customizable and accounts for chemical diversity and novelty, but also allows for the incorporation of the 3D metrics evaluated in Chapter 2. To demonstrate its utility, we used it to design and synthesize a focused set of cyclopropane-based 3D fragments as isolated cis- and trans-isomers. Chapter 4 details the synthesis of two focused libraries containing a total of 28 spirocyclic cyclobutane fragments, designed using the automated workflow described in Chapter 3. It describes the large-scale synthesis of diastereomerically pure building blocks and their parallel chemistry-based derivatization into the two focused libraries, each composed of isolated sets of achiral diastereomers. Chapter 5 describes the identification of a cyclobutane-based 3D fragment hit targeting the Histamine H1 receptor (H1R), discovered by screening a diverse 80-membered set of 3D fragments comprising various aliphatic (hetero)cyclic scaffolds. Following several rounds of SAR-driven optimization, the high-affinity antagonist VUF26691 (pKi = 8.8) was identified, with retention of the cyclobutane core throughout the optimization. Chapter 6 describes the development of the Exit Vector Fingerprint (EFVP) as a novel method for designing 3D fragment libraries. Rather than relying on overall molecular shape or atom hybridization, it employs exit vector geometry, combined with the pharmacophoric features residing on those vectors, as a more pharmacologically relevant basis for describing three-dimensionality. In addition to providing a practical tool for designing the next generation of 3D fragment libraries, the EVFP offers a refined conceptual framework for evaluating three-dimensional fragments. Finally, Chapter 7 provides an integrated discussion of the findings presented throughout the thesis and outlines future perspectives.